| Project/Area Number |
16591263
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
NAGATA Yasuhiro Nagasaki University, Hospital of Medicine and Dentistry, Assistant Professor, 医学部・歯学部附属病院, 講師 (80336164)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UDONO Heiichiro RIKEN YOKOHAMA INSTITUTE, Research Center for Allergy & Immunology, Team Leader, 横浜研究所, チームリーダー (50260659)
KANEMATSU Takashi Nagasaki University, Graduate School of Biomedical Sciences, Professor, 大学院・医歯薬学総合研究科, 教授 (40128004)
松尾 光敏 長崎大学, 医学部・歯学部附属病院, 助手 (00380840)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2004: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | Heat-shock protein / Cancer Vaccine / NY-ESO-1 / Dendritic Cell |
|---|
| Research Abstract |
Heat shock proteins(HSPs) 70 are a family of highly conserved molecules with ATPase activity and relative molecular masses around 70,000 kDa. Hsp proteins chaperone antigenic peptides into antigen-presenting cells, potentially allowing peptides to enter the MHC class I pathway for loading onto MHC class I molecules, where they can be presented to cytotoxic CD8+ T cells. In turn, this provides a strategy for immunization against cancer by using hsp and bound peptides that are isolated from tumors. Immunization with heat shock cognate protein 70 (hsc70) bound to synthetic peptides by in vitro reconstitution has been shown to induce peptide-specific CTL in mice. Here, we succeed genetically to fuse hsc70 and a CTL epitope derived from NY-ESO-1, one of the cancer-testis antigens. We also have shown dendritic cell can present the epitope onto their MHC class I after feeding the fusion protein. Hsc70 with NY-ESO-1 peptide can be processed through cytosolic pathway and presented by DCs to CD8^+ T cell clones. These findings help devising and validating vaccine strategies with Hsc-NY-ESO-1 epitope fusion protein.
|
